Skip Navigation LinksHome > February 20, 2004 - Volume 18 - Issue 3 > Rate of decline of absolute number and percentage of CD4 T l...
AIDS:
Basic Science: Concise Communications

Rate of decline of absolute number and percentage of CD4 T lymphocytes among HIV-1-infected adults in Dar es Salaam, Tanzania

Urassa, Willya; Bakari, Mohamedb; Sandström, Ericc; Swai, Andrewb; Pallangyo, Kisalib; Mbena, Ephraima; Mhalu, Freda; Biberfeld, Gunneld

Free Access
Article Outline
Collapse Box

Author Information

From the Departments of aMicrobiology and Immunology, and bInternal Medicine, Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania; cVenhälsan, Karolinska Institute at Söder Hospital, and d Swedish Institute for Infectious Diseases Control and Microbiology and Tumorbiology Center, Karolinska Institute, Stockholm, Sweden.

Correspondence to: Gunnel Biberfeld, Swedish Institute for Infectious Diseases Control and Karolinska Institute, SE-171 82 Solna, Sweden.

Tel: +46 0 8 457 2660; fax: +46 0 8 33 74 60; e-mail: gunnel.biberfeld@smi.ki.se

Received: 25 April 2002; revised: 31 July 2003; accepted: 13 August 2003.

Collapse Box

Abstract

Objective: To determine the rate of decline of CD4 T lymphocytes among HIV-1-infected individuals.

Design and setting: A prospective open cohort study of workers in three hotels in Dar es Salaam.

Methods: The workers were seen yearly during the study. CD4 T lymphocyte counts were determined using flow cytometry. The CD4 T-lymphocyte slopes were determined using a linear regression model.

Results: During the 9-year study period 682 subjects were selected for lymphocyte subset determinations. Of these, 94 HIV-1-seroprevalent (72%), 77 HIV-1-seroincident (67%) and 325 seronegative (75%) individuals had three or more CD4 T-cell determinations, and were used for calculations of CD4 cell slopes with a mean follow-up period of 71.4, 52.9 and 86.0 months, respectively. The median yearly decline of the CD4 T-lymphocyte counts and percentages among seroprevalent individuals was −21.5 cells/μl and −1.3%; among the seroincident individuals the median decline was −22.0 cells/μl and −1.5%. In seroincident individuals the mean duration to a CD4 T-lymphocyte level corresponding to a definition of AIDS was 13.3 years or 11.8 years for CD4 cell counts or percentages, respectively. HIV-1-seropositive subjects who died had significantly steeper CD4 cell slopes than those who survived.

Conclusion: The rates of CD4 T-lymphocyte decline in HIV-1-infected individuals in our population are similar to those reported in Europe and north America.

Back to Top | Article Outline

Introduction

It is well established that the cardinal immunopathological mechanism that leads to profound immunodeficiency in HIV infection is the progressive loss of CD4 T lymphocytes [1]. The HIV-1 viral load has been found to correlate with the rate of loss of CD4 T lymphocytes, representing the most commonly used prognostic markers in clinical practice [2,3]. The rate of loss of CD4 T lymphocytes in a significant proportion of HIV-infected individuals has been documented to be constant; however, considerable individual variation has been observed [4–9]. The rates of decline of CD4 T lymphocytes in HIV-infected individuals in Europe and north America have been reported in several populations [3,7,8]. However, studies that have compared the rate of disease progression and CD4 T lymphocyte decline in African and non-African populations living in the same geographical location have not been conclusive [5,6,8,10]. In a study in Nairobi involving sex workers, a rapid clinical progression from seroconversion to AIDS in a median period of 5 years was reported [11]. A recent study in Uganda [12] reported a median time from seroconversion to AIDS of 9.4 years, which is similar to that reported in Europe and north America. Factors including age, mode of infection, concurrent infections, HIV-1 biological phenotypes and HIV-1 subtypes have been suggested to influence HIV-1 disease progression [3,10,11,13–18].

We have determined the rate of decline of CD4 T lymphocytes among HIV-1-infected individuals with unknown dates of seroconversion (seroprevalent), HIV-1-infected individuals with known dates of seroconversion (seroincident) and HIV-uninfected subjects who were followed up for up to 9 years in Dar es Salaam, Tanzania.

Back to Top | Article Outline

Materials and methods

Subjects

The study subjects were recruited among hotel workers in Dar es Salaam, Tanzania from 1989 to 1998, in order to study the natural history of HIV-1 infection. After explaining the objectives of the study, hotel workers who consented were invited to participate in the study. The workers were interviewed and examined at recruitment and once per year. HIV testing was carried out after pre-test counselling, and post-test counselling was conducted with those who wanted to know their HIV test results. Lymphocyte subset determinations were carried out on individuals who were found to be HIV infected at recruitment (HIV-1 seroprevalent), on those who became HIV infected during the study period (HIV-1 seroincident) and on matched HIV-seronegative referents who gave verbal consent. Efforts were made to have two age and sex-matched HIV seronegative referents for every HIV-1-seropositive individual. The families, for financial reasons, regularly reported a death of a hotel worker back to the hotels. The closure of the hotels in 1998 resulted in the termination of the study. Over a span of 9 years, 1548 workers in three hotels comprising 163 HIV-1-seroprevalent (10.5%), 125 HIV-1-seroincident (8.1%) and 1260 HIV-seronegative (81.4%) individuals were recruited into this study of the progression of immunodeficiency (total study population).

The ethics committees of the National AIDS Control Programme of the Ministry of Health, Tanzania and Karolinska Institute, Stockholm, Sweden gave ethical approval for the study.

Back to Top | Article Outline
HIV testing

HIV antibodies in blood were demonstrated using Enzygnost anti-HIV-1+2 Plus enzyme-linked immunosorbent assay (Behring, Marburg, Germany). All reactive samples were examined using a Western blot assay (Genelab, USA), which was interpreted according to the World Health Organization criteria [19].

Back to Top | Article Outline
Lymphocyte subset determination

The immunophenotyping of lymphocyte subsets was performed using the SimulSET flow cytometry method (Immunocytometry System, Becton Dickinson, CA, USA) as described previously [20], and according to the standard guidelines for CD4 T-lymphocyte immunophenotyping in HIV-infected individuals [21].

Back to Top | Article Outline
Statistical analysis

Data analysis was performed using the Statistical Package for Social Scientists (SPSS 11.0; Norusis, SPSS Inc., Chicago, IL, USA). The distribution of the CD4 T-lymphocyte percentage was normal, whereas that of absolute CD4 T lymphocytes became normal after the removal of seven outliers (0.3%) out of 2539 measurements. CD4 T-lymphocyte slopes were obtained by fitting a linear regression model by the least square method for each patient. The projected rate of decline of CD4 T lymphocytes was obtained by fitting a linear regression line utilizing the median yearly loss of CD4 T cells for each category of HIV-1-infected individuals. Differences in the means and medians were calculated using the Student's t-test and Mann–Whitney test, respectively. One-way analysis of variance was used to compare several mean values and obtain within-person variance. The within-person coefficients of variation of CD4 T lymphocytes was obtained by dividing the square root of within-person variance (within-person standard deviation) by the mean multiplied by 100 on 55 HIV-seronegative individuals with seven CD4 lymphocyte determinations.

Back to Top | Article Outline

Results

T-lymphocyte subsets were studied in 80.4% of the HIV-1-seroprevalent (131/163), 92.0% of the HIV-1-seroincident (115/125) and 34.6% of the HIV-seronegative individuals (436/1260), who were recruited as matched referents for the HIV-seropositive individuals, giving a total of 682 individuals (lymphocyte population). Among those, data from 94 out of 131 HIV-1-seroprevalent (71.7%), 77 out of 115 HIV-1-seroincident (67.0%) and 325 out of 436 HIV-seronegative (74.5%) individuals who had three or more CD4 T-lymphocyte determinations were used for determination of the CD4 T-lymphocyte slope (CD4 cell slope population). None of the HIV-1-seropositive individuals was on antiretroviral treatment. The mean follow-up of the CD4 cell slope population was 71.4, 52.9 and 86.0 months for HIV-1 seroprevalent, seroincident and seronegative individuals, respectively.

There were no significant differences in the median age at recruitment among the CD4 cell slope population compared with those who were not included in the analysis (Table 1). The CD4 cell slope population had significantly higher baseline CD4 T-cell counts in both HIV-1-seroincident and seroprevalent individuals when compared with those who were not included in the CD4 cell slope analysis. The median slope of the CD4 T-cell counts for the first two visits was significantly steeper for the CD4 cell slope population among the seroprevalent individuals but was not significantly different among the seroincident individuals. The median slope of the CD4 cell percentage for the first two determinations was significantly steeper for the CD4 cell slope population among the seroincident individuals but not among the seroprevalent individuals compared with those who were excluded from the analysis (Table 1). There was thus no indication of a selection for steeper decline in those lost to follow-up, bearing in mind the large standard deviation when slopes are calculated from only two CD4 cell observations.

Table 1
Table 1
Image Tools
Back to Top | Article Outline
HIV-seronegative individuals

Among the 325 HIV-seronegative referents who had three or more CD4 T-lymphocyte determinations performed, there was more variability of the CD4 T-lymphocyte counts compared with CD4 cell percentages with coefficients of variation of 34.8% and 16.7%, respectively. Slopes calculated on CD4 T-lymphocyte counts seemed to indicate that there was a trend towards lower measurements with a median of −6.0 cells per year over the study period, whereas this was not the case for the CD4 cell percentage, which was 0.1.

Back to Top | Article Outline
CD4 T-cell decline among HIV-1-seroprevalent and seroincident individuals

The median yearly loss of CD4 T lymphocytes among HIV-1-seroprevalent and seroincident individuals was almost similar, −21.5 cells/μl or −1.3% for the absolute count and percentage, respectively in the former, and −22.0 cells/μl or −1.5% for the latter. There was no significant difference in the median decline of CD4 T lymphocytes between men and women. The HIV-1-seroprevalent individuals with high initial CD4 T lymphocytes were found to have a significantly steeper decline of CD4 T-lymphocyte counts but not CD4 cell percentages than those with lower baseline counts (Pearson's correlation coefficient r = −0.470, P < 0.01; r = −0.166, P = 0.10, respectively). There was no significant age-related difference in the mean or median CD4 T-lymphocyte decline among HIV-1-seroincident individuals. However, there were few HIV-1-seroincident individuals above the age of 40 years (4/77).

Among individuals with three or more CD4 T-lymphocyte determinations 20 out of 94 HIV-1-seroprevalent (21.3%) and 15 out of 77 seroincident (19.5%) individuals died. The median baseline CD4 T-lymphocyte counts were not significantly different among those who died compared with those who survived (data not shown), whereas among seroincident individuals the baseline CD4 cell percentage was significantly lower for those who died compared with those who survived (16 versus 27%, P < 0.01). The median yearly loss of CD4 T lymphocytes was −52.0 cells/μl for seroprevalent individuals who died compared with −18.5 cells/μl for those who survived (P = 0.10). In seroincident individuals the corresponding values were −69.0 cells/μl and −15.0 cells/μl, respectively (P < 0.01). In the case of the CD4 cell percentage, the median yearly loss was −2.9% among seroprevalent individuals who died compared with −1.2% for seroprevalent individuals who survived (P < 0.01), while for seroincident individuals the values were −2.2% and −1.1%, respectively (P = 0.02). In HIV-1-seroincident individuals the mean duration since infection for those who died was 58 months.

Back to Top | Article Outline
Calculated rate of decline

Fig. 1 shows the projected decline of CD4 T-lymphocyte counts and percentages in HIV-1-seroincident individuals. The median time to reach 200 CD4 T lymphocytes/μl was 13.3 years compared with 3.9 years for those who progressed fast and died. The time to reach the CD4 cell percentage corresponding to 200 CD4 T lymphocytes (9.8%) in this cohort [22] was 11.8 years compared with 4.4 years for those who died (Fig. 1b).

Fig. 1
Fig. 1
Image Tools
Back to Top | Article Outline

Discussion

We have followed a cohort of HIV-1-seroprevalent and seroincident hotel workers to determine the rate of decline of CD4 T lymphocytes. The rates of CD4 T-lymphocyte decline among HIV-seroprevalent and HIV-seroincident individuals were similar.

A comparison of the median CD4 T-lymphocyte slopes of the first two CD4 T-cell determinations between those with less than three CD4 cell determinations and those with three or more CD4 cell determinations did not show any tendency to a more rapid decline in the group with less than three determinations. It can therefore be implied that the exclusion of individuals with less than three CD4 T-cell determinations did not lead to a bias towards underestimating the CD4 T-cell decline.

We found a yearly median loss of −21.0 CD4 T lymphocytes/μl in prevalent HIV-1-infected individuals in our cohort, but as there was a decline of −6.0 cells/μl per year in the measurements in HIV-seronegative individuals over the period studied, the actual loss might thus be lower as measured by CD4 T-lymphocyte counts. In the present population, the CD4 T-lymphocyte percentage has been used to calculate CD4 T-lymphocyte counts [22]. Using this relationship and the observed CD4 cell percentage, the yearly loss can be calculated as −26.9 CD4 lymphocytes/μl. This calculation utilizes the lower variability of CD4 T-lymphocyte decline using the CD4 cell percentage and values from all the 2476 analysed samples during the study.

To the best of our knowledge, this study is the first report on the decline of CD4 T lymphocytes in HIV-1-infected subjects in Africa that includes absolute numbers as well as CD4 cell percentages. A study among Gambian seroprevalent HIV-1-infected individuals with a median follow-up of 2.1 years showed a yearly decline of −2.1 CD4 cell percentage [23], which is higher than the decline of the CD4 cell percentage in our study (−1.3% in HIV-1-seroprevalent subjects). The rate of decline of CD4 lymphocytes in our population is similar to what has been reported in HIV-1-infected subjects in the United States and Europe [8,10,24,25]. In our study there was no sex difference in the rate of decline of CD4 T-lymphocyte counts. However, in the Women Interagency HIV Study and the Multicenter AIDS Cohort Study, women had a more rapid decline of CD4 T-lymphocyte counts than men [10].

Therefore, we did not find evidence that the immune deterioration is faster in HIV-1-infected individuals in sub-Saharan Africa than in Europe and the United States. Moreover, a projection using data from our cohort showed that the time from seroconversion to AIDS was approximately 13.3 years when using CD4 T-lymphocyte counts (200 cells/μl) and 11.8 years when using the corresponding CD4 cell percentage, which is similar to the global median time to AIDS defined by the CD4 T-lymphocyte counts [1–3]. Our results from a general urban working population in Tanzania are also in agreement with results from a recent population-based study in Uganda, which reported that the median time from HIV-1 seroconversion to AIDS was similar to that reported from western countries [12]. In contrast, in a study in Nairobi, Kenya, restricted to female sex workers, the median time from seroconversion to clinical AIDS was less than 5 years [11].

Among the HIV-1-seroprevalent and seroincident individuals in the present study a significant proportion died and had experienced a significantly higher rate of loss of CD4 lymphocytes compared with those who survived. Similar patterns of decline of CD4 T lymphocytes have been reported elsewhere [25].

In the current study, serial CD4 T-lymphocyte counts in HIV-seronegative individuals were found to have more variability compared with the CD4 cell percentage, in agreement with previous studies [26,27]. Despite this limitation, it will be important to use both parameters, but bear in-mind the weakness of each when interpreting the data as it is unclear what values are more important in predicting the risk of complications to immunodeficiency.

In conclusion, the immunological deterioration of HIV-1-infected individuals in our Tanzanian population in which HIV-1 subtypes A, C and D are prevalent [28] is similar to that reported from the industrialized countries where HIV-1 subtype B is most common.

Back to Top | Article Outline

Acknowledgement

The authors would like to acknowledge all the hotel workers who agreed to participate in the study and all health workers who participated in the work.

Sponsorship: The study was supported by the Swedish International Development Agency (SIDA), Department of Research Cooperation (SAREC) as part of the TANSWED HIV programme.

Back to Top | Article Outline

References

1. Sotrel A, Dal Canto MC. HIV-1 and its causal relationship to immunosuppression and nervous system disease in AIDS: a review. Hum Pathol 2000, 31:1274–1298.

2. Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicentre AIDS Cohort Study. J Infect Dis 2000, 181:872–880.

3. Masel J, Arnaout RA, O'Brien TR, Goedert JJ, Lloyd AL. Fluctuations in HIV-1 viral load are correlated to CD4+ T-lymphocyte count during the natural course of infection. J Acquired Immune Defic Syndr 2000, 23:375–379.

4. Demarest JF, Jack N, Cleghorn FR, Grenberg ML, Hoffman TL, Ottinger JS, et al. Immunological and virological analysis of an acutely HIV type 1-infected patient with extremely rapid disease progression. AIDS Res Hum Retroviruses 2001, 17:1333–1344.

5. Easterbrook PJ, Farzadegan H, Hoover DR, Palenicek J, Chmiel JS, Kaslow RA, et al. Racial differences in rate of CD4 decline in HIV-1-infected homosexual men. AIDS 1996; 10:1147–1155.

6. Del Amo J, Petruckevitch A, Phillips A, Johnson AM, Stephenson J, Desmond N, et al. Disease progression and survival in HIV-1-infected Africans in London. AIDS 1998, 12:1203–1209.

7. Cozzi Lepri A, Sabin CA, Phillips AN, Lee CA, Pezzotti P, Rezza G. The rate of CD4 decline as a determinant of progression to AIDS independent of the most recent CD4 count. The Italian Seroconversion Study. Epidemiol Infect 1998, 121: 369–376.

8. Alaeus A, Lidman K, Bjorkman A, Giesecke J, Albert J. Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A–D. AIDS 1999, 13:901–907.

9. Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W. The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 1993, 7:1159–1166.

10. Anastos K, Gange SJ, Lau B, Weiser B, Detels R, Giorgi JV, et al. Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquired Immune Defic Syndr 2000; 24:218–226.

11. Anzala AO, Nagelkerke NJ, Bwayo JJ, Holton D, Moses S, Ngugi EN, et al. Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. J Infect Dis 1995, 171:686–689.

12. Morgan D, Mahe C, Mayanja B, Okongo M, Lubega R, Whitworth JA. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS 2002, 16:597–603.

13. Phillips AN, Lee CA, Elford J, Webster A, Janossy G, Timms A, et al. More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts. J Acquired Immune Defic Syndr 1991, 4:970–975.

14. Kanki PJ, Hamel DJ, Sankale JL, Hsieh CC, Thior I, Barin F, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999, 179:68–73.

15. Anzala AO, Simonsen JN, Kimani J, Ball TB, Nagelkerke NJ, Rutherford J, et al. Acute sexually transmitted infections increase human immunodeficiency virus type 1 plasma viremia, increase plasma type 2 cytokines, and decrease CD4 cell counts. J Infect Dis 2000, 182:459–466.

16. Kaleebu P, Ross A, Morgan D, Yirrell D, Oram J, Rutebemberwa A, et al. Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS 2000, 15:293–299.

17. Koot M, Keet I, Vos A, de Goede R, Ross M, Coutinho R, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993, 118:681–688.

18. Saag M, Hammer S, Lange J. Pathogenicity and diversity of HIV and implications for clinical management. J Acquired Immune Defic Syndr 1994, 7 (Suppl. 2):S2–S11.

19. WHO Global Program on AIDS. Proposed WHO criteria for interpretation of results from Western blot assay for HIV-1, HIV-2, and HTLV-HTLV-II. Wkly Epidemiol Rec 1990, 37:281–283.

20. Urassa WK, Mbena EM, Swai AB, Gaines H, Mhalu FS, Biberfled G. Lymphocyte subset enumeration in HIV seronegative and HIV-1 seropositve adults in Dar es Salaam, Tanzania: determination of reference values in males and females and comparison of two flow cytometric methods. J Immunol Methods 2003, 277: 65–74.

21. Centers for Disease Control and Prevention. 1997 Revised guidelines for performing CD4+ T-cell determinations in persons infected with human immunodeficiency virus (HIV). MMWR 1997, 46:1–29.

22. Sandstrom E, Urassa W, Bakari M, Swai A, Mhalu F, Biberfeld G, et al. Percent CD4 T-lymphocytes can be used to estimate CD4 T lymphocyte counts in HIV-1 infected subjects in sub-Saharan Africa. Int J STD AIDS 2003, 14:547–551.

23. Jaffar S, Wilkins A, Ngom PT, Sabally S, Corrah T, Bangali JE, et al. Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection. J Acquired Immune Defic Syndr Hum Retrovirol 1997, 16:327–332.

24. Margolick JB, Munoz A, Vlahov D, Solomon L, Astemborski J, Cohn S, et al. Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection. JAMA 1992, 267:1631–1636.

25. Lang W, Perkins H, Anderson RE, Royce R, Jewell N, Winkelstein W Jr. Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS. J Acquired Immune Defic Syndr 1989, 2:63–69.

26. Taylor JM, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4 : CD8 ratio in HIV infection: which to choose and how to use. J Acquired Immune Defic Syndr 1989, 2: 114–124.

27. Burcham J, Marmor M, Dubin N, Tindall B, Cooper DA, Berry G, et al. CD4% is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men. AIDS 1991, 5: 365–372.

28. Lyamuya E, Olausson-Hansson E, Albert J, Mhalu F, Biberfeld G. Evaluation of a prototype Amplicor PCR assay for detection of human immunodeficiency virus type 1 DNA in blood samples from Tanzanian adults infected with HIV-1 subtypes A, C and D. J Clin Virol 2000, 17:57–63.

Cited By:

This article has been cited 19 time(s).

Oncology Reports
Oral Kaposi's sarcoma in Tanzania: Presentation, immunopathology and human herpesvirus-8 association
Mwakigonja, AR; Pak, F; Pyakurel, P; Mosha, IJ; Urassa, WK; Kaaya, EE; Biberfeld, P
Oncology Reports, 17(6): 1291-1299.

Parasite Immunology
HIV-1 and intestinal helminth review update: Updating a Cochrane Review and building the case for treatment and has the time come to test and treat?
Alexander, PE; De, P
Parasite Immunology, 31(6): 283-286.
10.1111/j.1365-3024.2009.01100.x
CrossRef
Emerging Infectious Diseases
Malaria attributable to the HIV-1 epidemic, sub-Saharan Africa
Korenromp, EL; Williams, BG; de Vlas, SJ; Gouws, E; Gilks, CF; Ghys, PD; Nahlen, BL
Emerging Infectious Diseases, 11(9): 1410-1419.

Journal of Infectious Diseases
HIV infection, Antiretroviral therapy, and CD4(+) cell count distributions in African populations
Williams, BG; Korenromp, EL; Gouws, E; Schmid, GP; Auvert, B; Dye, C
Journal of Infectious Diseases, 194(): 1450-1458.

Scandinavian Journal of Infectious Diseases
The natural course of disease following HIV-1 infection in Dar es Salaam, Tanzania: A study among hotel workers relating clinical events to CD4(+) T-lymphocyte counts
Bakari, M; Urassa, W; Pallangyo, K; Swai, A; Mhalu, F; Biberfeld, G; Sandstrom, E
Scandinavian Journal of Infectious Diseases, 36(): 466-473.
10.1080/00365540410016249
CrossRef
AIDS
Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trial
Walson, JL; Otieno, PA; Mbuchi, M; Richardson, BA; Lohman-Payne, B; Macharia, SW; Overbaugh, J; Berkley, J; Sanders, EJ; Chung, MH; John-Stewart, GC
AIDS, 22(): 1601-1609.

Scandinavian Journal of Infectious Diseases
Slow progression of HIV-1 infection in a cohort of antiretroviral naive hotel workers in Dar es Salaam, Tanzania as defined by their CD4 cell slopes
Bakari, M; Urassa, W; Mhalu, F; Biberfeld, G; Pallangyo, K; Sandstrom, E
Scandinavian Journal of Infectious Diseases, 40(5): 407-413.
10.1080/00365540701708285
CrossRef
Journal of Infectious Diseases
Low CD4 T cell counts before HIV-1 seroconversion do not affect disease progression in Ethiopian factory workers
Mekonnen, Y; Geskus, RB; Hendriks, JCM; Messele, T; Borghans, J; Miedema, F; Wolday, D; Coutinho, RA; Dukers, NHTM
Journal of Infectious Diseases, 192(5): 739-748.

Colloidal Quantum Dots for Biomedical Applications
Automated Four Color CD4/CD8 Analysis of Leukocytes by Scanning Fluorescence Microscopy Using Quantum dots - art. no. 60960Z
Bocsi, J; Mittag, A; Varga, VS; Molnar, B; Tulassay, Z; Sack, U; Lenz, D; Tarnok, A
Colloidal Quantum Dots for Biomedical Applications, 6096(): Z960-Z960.
ARTN 60960Z
CrossRef
American Journal of Clinical Nutrition
Micronutrient supplementation has limited effects on intestinal infectious disease and mortality in a Zambian population of mixed HIV status: a cluster randomized trial
Kelly, P; Katubulushi, M; Todd, J; Banda, R; Yambayamba, V; Fwoloshi, M; Zulu, I; Kafwembe, E; Yavwa, F; Sanderson, IR; Tomkins, A
American Journal of Clinical Nutrition, 88(4): 1010-1017.

Journal of Infectious Diseases
Survival in women exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV: A stochastic model
Westreich, D; Eron, J; Behets, F; van der Horst, C; Van Rie, A
Journal of Infectious Diseases, 195(6): 837-846.
10.1086/511276
CrossRef
Journal of Infectious Diseases
CD4(+) T Cell Count Decreases by Ethnicity among Untreated Patients with HIV Infection in South Africa and Switzerland
May, M; Wood, R; Myer, L; Taffe, P; Rauch, A; Battegay, M; Egger, M
Journal of Infectious Diseases, 200(): 1729-1735.
10.1086/648096
CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater
Gras, L; Kesselring, AM; Griffin, JT; van Sighem, A; Fraser, C; Ghani, AC; Miedema, F; Reiss, P; Lange, JM; de Wolf, F; on Behalf of the ATHENA, Netherlands National Observational Cohort Study,
JAIDS Journal of Acquired Immune Deficiency Syndromes, 45(2): 183-192.
10.1097/QAI.0b013e31804d685b
PDF (507) | CrossRef
AIDS
Slow decline in CD4 cell count in a cohort of HIV-infected adults living in Lusaka, Zambia
Katubulushi, M; Zulu, I; Yavwa, F; Kelly, P
AIDS, 19(1): 102-103.

PDF (105)
AIDS
Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals
Pine, SO; McElrath, MJ; Bochud, P
AIDS, 23(18): 2387-2395.
10.1097/QAD.0b013e328330b489
PDF (359) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Response to “CD4 Cell Count Natural History and Informative Censoring in Sub-Saharan Africa”
Holmes, CB; Wood, R; Maartens, G; Freedberg, KA; Losina, E
JAIDS Journal of Acquired Immune Deficiency Syndromes, 44(4): 491.
10.1097/QAI.0b013e318030c9d7
PDF (72) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
CD4 Decline and Incidence of Opportunistic Infections in Cape Town, South Africa: Implications for Prophylaxis and Treatment
Holmes, CB; Wood, R; Badri, M; Zilber, S; Wang, B; Maartens, G; Zheng, H; Lu, Z; Freedberg, KA; Losina, E
JAIDS Journal of Acquired Immune Deficiency Syndromes, 42(4): 464-469.
10.1097/01.qai.0000225729.79610.b7
PDF (159) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Viral Load and CD4 Count Dynamics After HIV-1 Seroconversion in Homosexual and Bisexual Men in Rio de Janeiro, Brazil
Djomand, G; Duerr, A; Faulhaber, JC; Struchiner, CJ; Pacheco, AG; Barroso, PF; Melo, MF; Schechter, M
JAIDS Journal of Acquired Immune Deficiency Syndromes, 43(4): 401-404.
10.1097/01.qai.0000243117.21788.90
PDF (112) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
HIV-1 Viral Subtype Differences in the Rate of CD4+ T-Cell Decline Among HIV Seroincident Antiretroviral Naive Persons in Rakai District, Uganda
Kiwanuka, N; Robb, M; Laeyendecker, O; Kigozi, G; Wabwire-Mangen, F; Makumbi, FE; Nalugoda, F; Kagaayi, J; Eller, M; Eller, LA; Serwadda, D; Sewankambo, NK; Reynolds, SJ; Quinn, TC; Gray, RH; Wawer, MJ; Whalen, CC
JAIDS Journal of Acquired Immune Deficiency Syndromes, 54(2): 180-184.
10.1097/QAI.0b013e3181c98fc0
PDF (104) | CrossRef
Back to Top | Article Outline
Keywords:

Africa; CD4 T-lymphocyte decline; HIV-1; natural history

© 2004 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.